{"links":{"html":"https://www.erudio.com/reports/mevpro-1-nct06551324","json":"https://www.erudio.com/reports/mevpro-1-nct06551324.json","markdown":"https://www.erudio.com/reports/mevpro-1-nct06551324.md","mcp":{"server":"https://mcp.erudio.com/mcp","tool":"get_report_card","arguments":{"slug":"mevpro-1-06551324"}},"request":"https://www.erudio.com/contact?report=mevpro-1-06551324"},"offer":{"cited_commentary_sources":41,"verified_hcp_statements":284,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI. For scientific and insight use inside the organization, not for promotional targeting or outreach. Every report already names and describes its speakers.","available_with":"12-month updates","cap_usd":1250,"identity_verified_people":11,"optional":true,"price_per_verified_person_usd":15,"price_usd":165,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":1250,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_tools":["create_order","get_order","recover_key"],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"mevpro-1-nct06551324"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=mevpro-1-06551324","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/mevpro-1-nct06551324","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"standard","size_rule":"Standard: 151–300 verified statements","updates_usd":{"3_months":2200,"6_months":3100,"12_months":4400},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-19T02:20:43.260068Z","notify_subscribers":false,"status":"new","summary":{"reason":"Initial accepted edition has no weekly change log.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":11,"no_commentary_found":0},"aspects":[{"claim_count":5,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":4,"title":"Primary endpoint: Radiographic Progression Free Survival (rPFS) assessed by blinded independent central review (BICR) per RECIST v1.1 and Prostate Cancer Clinical Trials Working Group 3 (PCWG3)"},{"claim_count":6,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":5,"title":"Secondary endpoints"},{"claim_count":7,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":3,"title":"Population and setting"},{"claim_count":10,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":4,"title":"The comparison"},{"claim_count":10,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":6,"title":"Safety and tolerability"},{"claim_count":7,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":5,"title":"Design and conduct"},{"claim_count":23,"coverage":"discussed","id":"A1","source_count":6,"title":"EZH2 rationale, lineage plasticity and aggressive-variant disease"},{"claim_count":18,"coverage":"discussed","id":"A2","source_count":4,"title":"Biomarker work-up and applicability of PARP-based alternatives after prior ARPI"},{"claim_count":15,"coverage":"discussed","id":"A3","source_count":4,"title":"Radiopharmaceutical alternatives, skeletal protection and sequencing"},{"claim_count":16,"coverage":"discussed","id":"A4","source_count":4,"title":"Timely treatment, testing access and multidisciplinary support"},{"claim_count":14,"coverage":"discussed","id":"A5","source_count":1,"title":"Patient and caregiver experience of treatment switching and research access"}],"counts":{"cited_sources":41,"claims_by_expression_type":{"comparison":34,"experience":22,"interpretation":43,"opinion":64,"question":17,"restatement":39,"uncertainty":24,"unspecified":54},"claims_by_kind":{"attributed_opinion":5,"interpretation":13,"limitation":5,"source_observation":274},"clinician_statements":106,"evidence_units":183,"findings":9,"people_cited":20,"people_identity_verified":11,"people_total":21,"screened_sources":46,"verified_claims":284},"depth":"rich","findings_index":[{"id":"F1","structure":{"claims":11,"claims_by_group":{"comparisons":2,"experience":1,"questions":1,"restated":2,"views":5},"has_counterview":true,"limitations":3,"links":{"context":1,"support":12},"ma_question":true,"named_voices":5,"passages":8,"sources":4,"sources_by_kind":{"commentary":1,"media":3}},"title":"The consequential question is whether the combination offers a better next treatment—not merely a better ARPI switch"},{"id":"F2","structure":{"claims":11,"claims_by_group":{"comparisons":2,"experience":0,"questions":1,"restated":3,"views":5},"has_counterview":true,"limitations":3,"links":{"context":2,"support":13},"ma_question":true,"named_voices":4,"passages":7,"sources":5,"sources_by_kind":{"commentary":1,"media":4}},"title":"The earlier efficacy signal generates enthusiasm, but speakers still require pivotal confirmation"},{"id":"F3","structure":{"claims":13,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":6,"views":5},"has_counterview":true,"limitations":4,"links":{"context":3,"support":14},"ma_question":true,"named_voices":3,"passages":8,"sources":6,"sources_by_kind":{"commentary":1,"media":5}},"title":"Favorable tolerability assessments coexist with gastrointestinal burden and other visible adverse effects"},{"id":"F4","structure":{"claims":1,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":0,"views":0},"has_counterview":false,"limitations":3,"links":{"context":0,"support":1},"ma_question":true,"named_voices":1,"passages":1,"sources":1,"sources_by_kind":{"commentary":1}},"title":"One discussion questions whether PSA response has the same meaning across PRC2 inhibition and radioligand therapy"},{"id":"F5","structure":{"claims":15,"claims_by_group":{"comparisons":0,"experience":2,"questions":3,"restated":2,"views":8},"has_counterview":true,"limitations":3,"links":{"context":9,"support":24},"ma_question":true,"named_voices":6,"passages":12,"sources":5,"sources_by_kind":{"commentary":2,"media":3}},"title":"Resistance and lineage-plasticity biology explain interest, but prevention and biomarker selection remain hypotheses"},{"id":"F6","structure":{"claims":13,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":7,"views":5},"has_counterview":true,"limitations":4,"links":{"context":1,"support":35},"ma_question":true,"named_voices":3,"passages":10,"sources":3,"sources_by_kind":{"media":3}},"title":"Prior ARPI progression and molecular work-up constrain extrapolation from other combination strategies"},{"id":"F7","structure":{"claims":14,"claims_by_group":{"comparisons":4,"experience":2,"questions":1,"restated":2,"views":5},"has_counterview":true,"limitations":4,"links":{"context":2,"support":15},"ma_question":true,"named_voices":4,"passages":9,"sources":4,"sources_by_kind":{"media":4}},"title":"Radiopharmaceutical alternatives are patient- and timing-dependent, with bone protection and marrow burden central"},{"id":"F8","structure":{"claims":14,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":2,"views":10},"has_counterview":true,"limitations":4,"links":{"context":0,"support":18},"ma_question":true,"named_voices":3,"passages":13,"sources":4,"sources_by_kind":{"media":4}},"title":"Testing, timely sequencing and care infrastructure are implementation concerns—not secondary details"},{"id":"F9","structure":{"claims":14,"claims_by_group":{"comparisons":1,"experience":6,"questions":4,"restated":1,"views":2},"has_counterview":true,"limitations":4,"links":{"context":0,"support":15},"ma_question":true,"named_voices":0,"passages":9,"sources":1,"sources_by_kind":{"media":1}},"title":"Patient and caregiver accounts add access context but are not evidence of HCP endorsement or comparative efficacy"}],"medical_affairs_question":"What evidence would distinguish a clinically useful alternative to docetaxel from an improvement over enzalutamide switching alone?","sections":{"analysis":[{"id":"section-1","level":2,"title":"A useful next treatment must compete with more than an ARPI switch"},{"id":"section-2","level":2,"title":"Enthusiasm rests on earlier data, not a MEVPRO-1 outcome"},{"id":"section-3","level":2,"title":"Manageability must be read alongside the actual treatment burden"},{"id":"section-4","level":2,"title":"PSA response and rPFS may not carry identical implications across mechanisms"},{"id":"section-5","level":2,"title":"Resistance biology supports a hypothesis, not proven prevention of aggressive transformation"},{"id":"section-6","level":2,"title":"Prior therapy and molecular findings determine which alternative evidence applies"},{"id":"section-7","level":2,"title":"Radiopharmaceutical placement remains conditional on disease distribution, safety and timing"},{"id":"section-8","level":2,"title":"Access to testing, multiple lines and capable teams can determine practical value"},{"id":"section-9","level":2,"title":"Patient accounts illuminate access without establishing clinical recommendations"},{"id":"section-10","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F2","shared_claims":4},{"id":"F4","shared_claims":1}],"id":"T1","label":"Primary endpoint: Radiographic Progression Free Survival (rPFS) assessed by blinded independent central review (BICR) per RECIST v1.1 and Prostate Cancer Clinical Trials Working Group 3 (PCWG3)"},{"findings":[{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":3},{"id":"F4","shared_claims":1}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F6","shared_claims":6}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":7}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":10}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":1}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-19T02:20:43.260068Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-19T02:34:45Z","record_hash":"b1e645dad6efeaa3de65c6a92150a68337bee0f39167bab3dd9fec4267769daf","release_hash":"6a4f7362ff34fc7a2804b9273826ff3774d8c7358ca61dd1380fa22b4f629412","report_id":"erudio-nct06551324","run_id":"974521ea-d437-420b-8e79-17f9cb80d5a6","schema_version":"5.0","slug":"mevpro-1-06551324","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"MEVPRO-1 asks which treatment should come next after abiraterone in metastatic castration-resistant prostate cancer, comparing mevrometostat plus enzalutamide with docetaxel or enzalutamide. Clinicians discuss how to assess that choice through earlier efficacy and safety evidence, PSA and imaging outcomes, resistance biology, lineage plasticity and biomarker work-up. Other topics include PARP-based and radiopharmaceutical alternatives, treatment sequencing, and access to testing, multidisciplinary care and clinical trials.","meta_description":"46 sources screened · 284 verified statements (106 from speakers with a confirmed clinical role) from 41 sources · 9 findings. Updated Oct 19, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-8ffc4869d5b26992454a","claim-dad27d518853d4ad4e34"],"id":"F1","paraphrase":"A YouTube panel addressed what MEVPRO-1 should clarify about treatment after abiraterone, including the choice between docetaxel and mevrometostat plus enzalutamide.","publication_caveats":["The discussion concerns an individual patient and does not present MEVPRO-1 treatment outcomes."],"source_channel":"youtube","source_date":"2025-06-25","title":"The consequential question is whether the combination offers a better next treatment—not merely a better ARPI switch"},{"cited_claim_ids":["claim-400a87df54bec3bd36e2"],"id":"F4","paraphrase":"An X-thread discussion raised how PSA response relates to radiographic progression-free survival when considering mevrometostat plus enzalutamide alongside radioligand therapy.","publication_caveats":["The author's clinical role is not stated in the sources reviewed for this edition.","The combination population included patients previously treated with taxanes, whereas the radioligand population was taxane-naive.","The cited predictor analysis was post-hoc and concerned radioligand treatment. The MEVPRO-1 question was forward-looking, not a report of its results."],"source_channel":"x_thread","source_date":"2026-04-01","title":"One discussion questions whether PSA response has the same meaning across PRC2 inhibition and radioligand therapy"}]},"publication":{"approved_at":"2026-10-19T02:34:45Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":46},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","2 cited commentary passages leave a source question open, such as who was speaking. The report attributes no further than the source shows.","Some clinician views in the sources used in this report are not yet captured as evidence in this edition; the next refresh takes them up.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","Out of scope: 8 passages in the reviewed sources discuss other trials or topics outside this report's scope; they are not part of this edition.","147 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed for this edition do not represent all HCPs or all public discussion, and trial-unnamed discussion may be underrepresented.","Some relevant discussion of PARP-combination alternatives and biomarker-based selection was not fully evaluated; the range of views may therefore be incomplete.","Repeated posts and multiple recordings of the same session cannot be counted as independent clinician opinions or separate clinical experiences.","Some speakers remain unidentified. Titles, participant lists and professional profiles do not establish who voiced those passages.","Clinical roles for Emir C. Roach, Rashid K. Sayyid and Rishabh Jain are not established in the sources reviewed. Patient, caregiver, publisher and financial commentary should not be treated as independent HCP judgment.","Earlier efficacy and safety observations are speaker reports from supporting studies, not MEVPRO-1 phase III outcomes. Differences in reported study phase and prior chemotherapy exposure remain unresolved.","Contemporaneous trial-design descriptions are inconsistent about the control comparison. The complete protocol was unavailable, so these remarks cannot resolve operational details.","An exact mevrometostat regulatory label was unavailable. Speaker descriptions of approvals, eligibility and reimbursement reflect their stated time and geography rather than independently verified current guidance.","Several numerical estimates concern selected databases, small groups, post-hoc analyses or individual experience; they do not support population-wide rates, causal comparisons or a treatment hierarchy.","Support-group treatment and insurance accounts are personal reports. They cannot establish comparative efficacy, molecular eligibility, payment guarantees or recommended self-directed treatment."]},"sources":{"cited_sources":{"by_channel":{"other":0,"podcast":2,"publication":0,"registry":0,"regulatory":0,"x_thread":31,"x_video":0,"youtube":8},"by_evidence_role":{"commentary":41},"count":41,"evidence_window":{"end":"2026-10-01","start":"2024-12-04"},"retrieval_snapshot":"2026-10-18T23:50:13.804034Z","timeline":[{"count":1,"week":"2024-W49"},{"count":1,"week":"2024-W51"},{"count":1,"week":"2025-W04"},{"count":3,"week":"2025-W07"},{"count":4,"week":"2025-W08"},{"count":1,"week":"2025-W10"},{"count":1,"week":"2025-W12"},{"count":1,"week":"2025-W16"},{"count":2,"week":"2025-W20"},{"count":2,"week":"2025-W23"},{"count":1,"week":"2025-W25"},{"count":3,"week":"2025-W26"},{"count":1,"week":"2025-W31"},{"count":1,"week":"2025-W34"},{"count":1,"week":"2025-W39"},{"count":1,"week":"2025-W42"},{"count":2,"week":"2025-W43"},{"count":1,"week":"2025-W48"},{"count":1,"week":"2025-W49"},{"count":1,"week":"2026-W01"},{"count":1,"week":"2026-W02"},{"count":1,"week":"2026-W09"},{"count":1,"week":"2026-W14"},{"count":2,"week":"2026-W18"},{"count":1,"week":"2026-W20"},{"count":1,"week":"2026-W23"},{"count":1,"week":"2026-W28"},{"count":1,"week":"2026-W32"},{"count":1,"week":"2026-W36"},{"count":1,"week":"2026-W40"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT06551324:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06551324:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:42108644","quote_policy":"no_derivatives"},{"id":"openfda:2992d633-08fa-44f3-b14d-41700f24686b:20260415","quote_policy":"short_quote_link_out"},{"id":"openfda:b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf:20260728","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:5fa930","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:6549fb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1864422910741434819:5d6baa1c-cd62-4ad2-8e52-d2e0fc52a586","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1868657405933858945:66e38ea4-729e-4e47-bf31-bf0d01b7643b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1882413089749950820:4d0dfb3c-8e1d-4b33-8e69-8a01b7d085d6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1890164272799576531:17a6be43-95f1-45cc-92d2-46642914affa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1890212660324847776:d605e3f4-c379-488c-b598-a9584008035d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1890213258247782566:c5ae5d3b-8b48-4cb4-aef3-7752ab34f11d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1891952167176573187:eba4d5e0-c391-4455-abe5-e723ef2daf0d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1892758919308525727:adf64c75-441e-4615-bc35-206aafc5809c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1892982735783727131:ff48a338-002c-4760-b6bd-9700f87d4e76","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1902752138821828658:9c0081d3-a69b-412a-82c2-87aadf3fd768","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1912174201990939042:07c7a6f1-50a1-4edf-a69a-f07c7ffdf340","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1922683443508355080:8947b439-c93c-4b80-9bfc-458dd3e306e8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929600082199884263:3f04bf85-50ec-4cb5-9c62-780b29361b81","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929919863000018981:a5702151-74e4-43dc-a288-298ee387ffee","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1938512467912483279:2d084453-0e04-4af0-8fcb-51741940d9cf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1938512629976240564:98276bc5-5192-4194-8029-e7ad5c9872ac","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1951013789840580746:ab93480e-dbb9-44f4-a7a3-30066dfe0852","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1958986320329462175:3ae6ba7d-b41d-4da3-80eb-fe4aad17aa03","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1969619834875900134:cc4ea925-6445-4e7a-8dc5-face220b21c5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1970220343156412782:237030ff-f6a6-49a4-89c5-6d942e0ae2dc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1978871148818636935:790c1198-0e53-4a46-b1dd-57fa09fe1d20","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980729587874099617:b63f9748-2b4c-48b1-8ddb-06574a573b9d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1991488789987094970:02aa1568-0e6f-4e23-8024-c59be6019781","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1993065879689420925:4e787a0e-3509-43de-91fd-37c400a1baed","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2026286371137003897:d9ad9af7-0373-4cde-a845-930d40dbef8e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2039367405042884864:f1e6d318-f2cb-4ee2-af9b-84f0ce2fdfc7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2044880261305844107:df6844a6-c205-488e-b8c8-db0b95d72768","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2050511552919257494:927fde40-f73e-4169-8408-570031e2c124","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2050727031273381990:66bba128-1bb6-4b23-9d2a-370f1894fe47","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2055237364960641244:30b1237d-a2b1-42eb-984c-38b6f599f023","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2062546210456506807:e29401e1-06c5-485a-974a-54f63f9c46cd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2074176604008337537:cc46c34a-b1a3-4231-8734-219c307363fa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2084685853306048734:059044e0-2f37-4bd8-aba3-a85ba17bd94a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095919876082667876:a26c86e4-7c28-4eaa-8c2c-e63affa24228","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2105628866861547918:d16ab06c-e749-46ad-93af-6495c48b83b3","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:0XfrF6V1Kro","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:CGkmSo4dWi8","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:DbeYMuV_tdo","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:GXraDswIwSs","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:NMLhnKVpTas","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:jnab5Lr_D4I","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:vB99JSxmeHU","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:xQlJ4Q98xN8","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:y9gJd7bQavA","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"other":0,"podcast":2,"publication":0,"registry":0,"regulatory":0,"x_thread":35,"x_video":0,"youtube":9},"by_evidence_role":{"commentary":46},"count":46,"evidence_window":{"end":"2026-10-16","start":"2024-12-04"},"retrieval_snapshot":"2026-10-18T23:50:13.804034Z","timeline":[{"count":1,"week":"2024-W49"},{"count":1,"week":"2024-W51"},{"count":1,"week":"2025-W04"},{"count":3,"week":"2025-W07"},{"count":4,"week":"2025-W08"},{"count":1,"week":"2025-W10"},{"count":1,"week":"2025-W12"},{"count":1,"week":"2025-W16"},{"count":2,"week":"2025-W20"},{"count":2,"week":"2025-W23"},{"count":1,"week":"2025-W25"},{"count":3,"week":"2025-W26"},{"count":1,"week":"2025-W31"},{"count":1,"week":"2025-W34"},{"count":1,"week":"2025-W38"},{"count":1,"week":"2025-W39"},{"count":1,"week":"2025-W42"},{"count":2,"week":"2025-W43"},{"count":1,"week":"2025-W47"},{"count":1,"week":"2025-W48"},{"count":1,"week":"2025-W49"},{"count":1,"week":"2026-W01"},{"count":1,"week":"2026-W02"},{"count":1,"week":"2026-W09"},{"count":1,"week":"2026-W14"},{"count":1,"week":"2026-W16"},{"count":3,"week":"2026-W18"},{"count":1,"week":"2026-W20"},{"count":1,"week":"2026-W23"},{"count":1,"week":"2026-W28"},{"count":1,"week":"2026-W32"},{"count":1,"week":"2026-W36"},{"count":1,"week":"2026-W40"},{"count":1,"week":"2026-W42"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: pf-06821497","status":"unmapped"},{"brand_names":["Taxotere"],"label":"docetaxel","slug":"docetaxel"},{"brand_names":["Xtandi"],"label":"enzalutamide","slug":"enzalutamide"}],"indications":[{"reason":"Unmapped registry condition: Metastatic Castrate Resistant Prostate Cancer (mCRPC)","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"MEVPRO-1","aliases":["MEVPRO-1","A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).","A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE (MEVPRO-1)"],"brief_title":"A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Metastatic Castrate Resistant Prostate Cancer (mCRPC)"],"enrollment":{"count":600,"type":"ESTIMATED"},"interventions":[{"name":"PF-06821497","synonyms":["Mevrometostat"],"type":"DRUG"},{"name":"Docetaxel","synonyms":["Taxotere"],"type":"DRUG"},{"name":"Enzalutamide","synonyms":["XTANDI"],"type":"DRUG"}],"nct_id":"NCT06551324","official_title":"A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE (MEVPRO-1)","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2026-12-28","type":"ESTIMATED"},"primary_endpoints":[{"description":"rPFS is defined as the time from the date of randomization to first objective evidence of radiographic progression as assessed in soft tissue per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or in bone per Prostate Cancer Clinical Trials Working Group 3 (PCWG3) guidelines by BICR, or death, whichever occurs first.","measure":"Radiographic Progression Free Survival (rPFS) assessed by blinded independent central review (BICR) per RECIST v1.1 and Prostate Cancer Clinical Trials Working Group 3 (PCWG3)","timeFrame":"Randomization up to approximately 2 years."}],"registry_last_updated":"2026-08-11","registry_url":"https://clinicaltrials.gov/study/NCT06551324","short_name":"MEVPRO-1","short_name_basis":"registry_acronym","sponsor":"Pfizer","start_date":{"date":"2024-10-21","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"C2321014","type":"sponsor_study_id"},{"domain":"CTIS (EU)","id":"2024-511650-50-00","type":"registry"}],"study_type":"INTERVENTIONAL"}}}